TNF inhibitors double risk of infections

In this large cohort of RA patients, those on TNF inhibitors had 2.4 times the risk of serious infections compared to those on non-biologic anti-rheumatic drugs. This infectious risk should always be considered in patients on TNF inhibitors (abstract)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment